Creative Biolabs has announced the expansion of its advanced single-cell multi-omics and RNA sequencing solutions, a move that promises to accelerate biomedical discovery by enabling researchers to profile thousands of individual cells with high sensitivity and coverage. The upgraded suite of services is designed to meet the growing demand for high-resolution cellular profiling, offering end-to-end workflows that range from single-cell transcriptome profiling to integrated multimodal and multi-omics analyses. This development matters because it addresses a critical bottleneck in life science research: the need to dissect cellular heterogeneity at single-cell resolution to identify rare cell subpopulations, characterize complex tumor microenvironments, and trace cell lineage trajectories.
As research increasingly transitions from bulk tissue profiling to single-cell resolution, the ability to analyze individual cells has become essential for precision medicine and biomarker discovery. Creative Biolabs now provides robust, high-throughput single-cell RNA sequencing services that deliver high-resolution transcriptomic insights from diverse fresh biological specimens. This service is particularly important for oncology and immunology research, where understanding the heterogeneity of cells within a tumor or immune response can reveal novel therapeutic targets and resistance mechanisms.
A key challenge in single-cell research has been processing complex, fibrous, or biobanked archival samples. Traditional single-cell dissociation methods can damage cells, induce stress responses, or lead to the selective loss of fragile cell types—such as those found in human brain, myocardium, or flash-frozen clinical biopsies. To overcome this, Creative Biolabs has introduced specialized single-nucleus RNA sequencing (snRNA-seq) capabilities. By isolating intact nuclei, this approach bypasses harsh enzymatic dissociation and minimizes dissociation-related artifacts while retaining informative nuclear RNA profiles. This dramatically expands the scope of clinical translational research, allowing scientists to analyze archived samples that were previously inaccessible.
Recognizing that cellular identity is orchestrated across multiple regulatory layers, Creative Biolabs has also advanced its high-throughput single-cell multi-omics service. This integrated platform allows the simultaneous interrogation of genomic variations, epigenomic landscapes (such as chromatin accessibility), cell surface proteomics (CITE-seq), and transcriptomes within identical single cells. By directly linking epigenetic regulation and genomic alterations to gene expression readouts, the service enables researchers to construct multi-dimensional cellular atlases and uncover novel therapeutic targets with unprecedented biological clarity.
According to a senior scientist at Creative Biolabs, understanding biology at single-cell and single-nucleus resolution is no longer a luxury but fundamental to precision medicine and biomarker discovery. The company's goal is to provide a seamless, modular analytical ecosystem that transforms difficult biological samples into reliable, high-dimensional datasets with rigorous bioinformatics support. Supported by advanced microfluidics technologies, stringent quality control benchmarks, and tailored bioinformatics pipelines, Creative Biolabs continues to partner with academic and biopharmaceutical research teams worldwide to unravel the complexities of human disease.
The implications of this expansion are significant for the biomedical research community. By offering a comprehensive suite of single-cell solutions, Creative Biolabs is empowering researchers across oncology, immunology, and neuroscience to generate richer, more actionable data from limited or challenging samples. This could lead to faster identification of therapeutic targets, better understanding of disease mechanisms, and more effective personalized treatments. As the field moves toward multi-omics integration, such services are likely to become indispensable tools for translational research and drug development.
